Topic collection
Bone peptide medicines
Fracture prevention in the studied osteoporosis population does not prove faster healing or safe performance use.
Start here
Start with these posts
Keep fracture prevention in osteoporosis separate from claims about faster healing, sports recovery, or performance.
Peptide records
Open each record to see its evidence.
Health results for approved uses
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use in the reviewed sources. It does not mean the product is safe or effective for everyone.Teriparatide
An established osteoporosis medicine that can reduce fracture risk in defined groups. Its evidence does not apply to every fracture-healing claim.
3 fact checks · Open the review ↗Health results for approved uses
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.EstablishedAn official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use in the reviewed sources. It does not mean the product is safe or effective for everyone.Abaloparatide
An approved osteoporosis medicine with fracture evidence in defined groups and product-specific safety limits.
3 fact checks · Open the review ↗
More about this topic
Both peptides reviewed here—teriparatide and abaloparatide—are graded Established, and both have FDA-approved products. Their approvals cover defined osteoporosis populations at high fracture risk, and the trials behind them measured fracture prevention over a set treatment period.
Preventing fractures in people at high risk from osteoporosis does not prove faster fracture healing or better sports recovery. It also does not prove benefits for people without the condition studied. Each review keeps the label's patient groups, limits on treatment length, and warnings with the result.
Questions to ask about this topic
- 01
Was the outcome fracture prevention, bone density, or acute fracture healing?
- 02
Which people with osteoporosis and a high risk of fractures took part?
- 03
Does the claim preserve label warnings and duration limits?